sacituzumab govitecan Trodelvy
Selected indexed studies
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. (N Engl J Med, 2021) [PMID:33882206]
- Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. (Lancet, 2023) [PMID:37633306]
- Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. (N Engl J Med, 2025) [PMID:41124233]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. (2021) pubmed
- Sacituzumab Govitecan. (2006) pubmed
- Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. (2023) pubmed
- Sacituzumab Govitecan. (2012) pubmed
- Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. (2025) pubmed
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. (2019) pubmed
- Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. (2026) pubmed
- Sacituzumab govitecan (Trodelvy) for metastatic triple-negative breast cancer. (2021) pubmed
- Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. (2022) pubmed
- Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. (2024) pubmed